185 related articles for article (PubMed ID: 32648337)
21. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells
Kuittinen T; Rovio P; Luukkaala T; Laurila M; Grénman S; Kallioniemi A; Mäenpää J
Anticancer Res; 2020 Jun; 40(6):3129-3138. PubMed ID: 32487607
[TBL] [Abstract][Full Text] [Related]
22. Metformin and epithelial ovarian cancer therapeutics.
Patel S; Kumar L; Singh N
Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
[TBL] [Abstract][Full Text] [Related]
24. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
25. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
26. Effects and mechanisms of anti-CD44 monoclonal antibody A3D8 on proliferation and apoptosis of sphere-forming cells with stemness from human ovarian cancer.
Du YR; Chen Y; Gao Y; Niu XL; Li YJ; Deng WM
Int J Gynecol Cancer; 2013 Oct; 23(8):1367-75. PubMed ID: 24257550
[TBL] [Abstract][Full Text] [Related]
27. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
[TBL] [Abstract][Full Text] [Related]
28. Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer.
Kievit E; Pinedo HM; Schlüper HM; Haisma HJ; Boven E
Int J Cancer; 1997 Apr; 71(2):237-45. PubMed ID: 9139849
[TBL] [Abstract][Full Text] [Related]
29. The Novel IκB Kinase β Inhibitor, IMD-0560, Has Potent Therapeutic Efficacy in Ovarian Cancer Xenograft Model Mice.
Sawada I; Hashimoto K; Sawada K; Kinose Y; Nakamura K; Toda A; Nakatsuka E; Yoshimura A; Mabuchi S; Fujikawa T; Itai A; Kimura T
Int J Gynecol Cancer; 2016 May; 26(4):610-8. PubMed ID: 26905334
[TBL] [Abstract][Full Text] [Related]
30. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
31. Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells.
Fraser M; Chan SL; Chan SS; Fiscus RR; Tsang BK
Oncogene; 2006 Apr; 25(15):2203-12. PubMed ID: 16288207
[TBL] [Abstract][Full Text] [Related]
32. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.
Landen CN; Kim TJ; Lin YG; Merritt WM; Kamat AA; Han LY; Spannuth WA; Nick AM; Jennnings NB; Kinch MS; Tice D; Sood AK
Neoplasia; 2008 Nov; 10(11):1259-67. PubMed ID: 18953435
[TBL] [Abstract][Full Text] [Related]
33. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B
Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
[TBL] [Abstract][Full Text] [Related]
34. The alpha2 and alpha3 integrins are required for morphologic differentiation of an intestinal epithelial cell line.
Zhang X; Cromwell JW; Kunjummen BD; Yee D; Garcia-Aguilar J
Surgery; 2003 Apr; 133(4):429-37. PubMed ID: 12717361
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxicity and apoptosis of ovarian and breast cancer cell lines induced by OVS1 monoclonal antibody and paclitaxel.
Moongkarndi P; Kaslungka S; Kosem N; Junnu S; Jongsomboonkusol S; Theptaranon Y; Neungton N
Asian Pac J Allergy Immunol; 2003 Mar; 21(1):31-41. PubMed ID: 12931749
[TBL] [Abstract][Full Text] [Related]
36. High Expression of Integrin α3 Predicts Poor Prognosis and Promotes Tumor Metastasis and Angiogenesis by Activating the c-Src/Extracellular Signal-Regulated Protein Kinase/Focal Adhesion Kinase Signaling Pathway in Cervical Cancer.
Du Q; Wang W; Liu T; Shang C; Huang J; Liao Y; Qin S; Chen Y; Liu P; Liu J; Yao S
Front Oncol; 2020; 10():36. PubMed ID: 32117712
[No Abstract] [Full Text] [Related]
37. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
Zhu X; Xu J; Cai H; Lang J
J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
[TBL] [Abstract][Full Text] [Related]
38. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
Li H; Qian Y; Wang X; Pi R; Zhao X; Wei X
Cell Prolif; 2020 Jan; 53(1):e12719. PubMed ID: 31778258
[TBL] [Abstract][Full Text] [Related]
39. α integrin targeting for radiosensitization of three-dimensionally grown human head and neck squamous cell carcinoma cells.
Steglich A; Vehlow A; Eke I; Cordes N
Cancer Lett; 2015 Feb; 357(2):542-8. PubMed ID: 25497870
[TBL] [Abstract][Full Text] [Related]
40. Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma.
Dong Y; Tan OL; Loessner D; Stephens C; Walpole C; Boyle GM; Parsons PG; Clements JA
Cancer Res; 2010 Apr; 70(7):2624-33. PubMed ID: 20332224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
